Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients.
about
Optimization therapy for the treatment of chronic hepatitis BHepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility.Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analoguesHBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients.ELISA for Quantitative Determination of Hepatitis B Virus Surface Antigen.
P2860
Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients.
@ast
Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients.
@en
type
label
Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients.
@ast
Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients.
@en
prefLabel
Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients.
@ast
Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients.
@en
P2093
P2860
P356
P1476
Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients.
@en
P2093
Etsuro Orito
Hiroshi Kanie
Katsumi Hayashi
Kei Fujiwara
Tesshin Ban
Tomonori Yamada
P2860
P304
P356
10.3748/WJG.V18.I39.5570
P407
P577
2012-10-01T00:00:00Z